Global Artificial Blood Substitute 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01253598

Publication Date:

January 29, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Artificial Blood Substitute market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of 23.2% from 2025 to 2031.
Artificial blood refers to artificial blood cells and their functional substitutes. Its function, as the name suggests, is to replace real human blood to meet people"s demand for blood and make up for the current blood shortage.
Artificial blood substitutes are used as oxygen therapy agents for emergency resuscitation and disease treatment. They have very important practical significance in developing countries and field hospitals that lack blood and urgently need blood transfusion, lack refrigeration equipment, and even on the battlefield. At the same time they do have great potential in reducing the spread of infectious diseases and providing new options for religious people who refuse blood transfusions.
Despite the huge application prospects, these artificial blood products all face some common problems. In addition to the safety and efficacy to be verified by clinical trials, the current production scale still needs to be greatly increased, and the production cost needs to be greatly reduced to meet the future demand for artificial blood .
The 鈥淎rtificial Blood Substitute Industry Forecast鈥� looks at past sales and reviews total world Artificial Blood Substitute sales in 2024, providing a comprehensive analysis by region and market sector of projected Artificial Blood Substitute sales for 2025 through 2031. With Artificial Blood Substitute sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Artificial Blood Substitute industry.
This Insight Report provides a comprehensive analysis of the global Artificial Blood Substitute landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Artificial Blood Substitute portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Artificial Blood Substitute market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Artificial Blood Substitute and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Artificial Blood Substitute.
This report presents a comprehensive overview, market shares, and growth opportunities of Artificial Blood Substitute market by product type, application, key players and key regions and countries.
Segmentation by Type:
Perfluorocarbon-based Oxygen Carrier (PFBOC)
Hemoglobin-based Oxygen Carrier (HBOC)
Segmentation by Application:
Military
Civil
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Aurum Biosciences Ltd.
HEMARINA SA
HbO2 Therapeutics
KaloCyte Inc.
SpheriTech Ltd.
NuvOx Pharma

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Artificial Blood Substitute 麻豆原创 Size (2020-2031)
2.1.2 Artificial Blood Substitute 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Artificial Blood Substitute by Country/Region (2020, 2024 & 2031)
2.2 Artificial Blood Substitute Segment by Type
2.2.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
2.2.2 Hemoglobin-based Oxygen Carrier (HBOC)
2.3 Artificial Blood Substitute 麻豆原创 Size by Type
2.3.1 Artificial Blood Substitute 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Artificial Blood Substitute 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Artificial Blood Substitute Segment by Application
2.4.1 Military
2.4.2 Civil
2.5 Artificial Blood Substitute 麻豆原创 Size by Application
2.5.1 Artificial Blood Substitute 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Artificial Blood Substitute 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Artificial Blood Substitute 麻豆原创 Size by Player
3.1 Artificial Blood Substitute 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Artificial Blood Substitute Revenue by Player (2020-2025)
3.1.2 Global Artificial Blood Substitute Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Artificial Blood Substitute Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Artificial Blood Substitute by Region
4.1 Artificial Blood Substitute 麻豆原创 Size by Region (2020-2025)
4.2 Global Artificial Blood Substitute Annual Revenue by Country/Region (2020-2025)
4.3 Americas Artificial Blood Substitute 麻豆原创 Size Growth (2020-2025)
4.4 APAC Artificial Blood Substitute 麻豆原创 Size Growth (2020-2025)
4.5 Europe Artificial Blood Substitute 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Artificial Blood Substitute 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Artificial Blood Substitute 麻豆原创 Size by Country (2020-2025)
5.2 Americas Artificial Blood Substitute 麻豆原创 Size by Type (2020-2025)
5.3 Americas Artificial Blood Substitute 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Artificial Blood Substitute 麻豆原创 Size by Region (2020-2025)
6.2 APAC Artificial Blood Substitute 麻豆原创 Size by Type (2020-2025)
6.3 APAC Artificial Blood Substitute 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Artificial Blood Substitute 麻豆原创 Size by Country (2020-2025)
7.2 Europe Artificial Blood Substitute 麻豆原创 Size by Type (2020-2025)
7.3 Europe Artificial Blood Substitute 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Artificial Blood Substitute by Region (2020-2025)
8.2 Middle East & Africa Artificial Blood Substitute 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Artificial Blood Substitute 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Artificial Blood Substitute 麻豆原创 Forecast
10.1 Global Artificial Blood Substitute Forecast by Region (2026-2031)
10.1.1 Global Artificial Blood Substitute Forecast by Region (2026-2031)
10.1.2 Americas Artificial Blood Substitute Forecast
10.1.3 APAC Artificial Blood Substitute Forecast
10.1.4 Europe Artificial Blood Substitute Forecast
10.1.5 Middle East & Africa Artificial Blood Substitute Forecast
10.2 Americas Artificial Blood Substitute Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Artificial Blood Substitute Forecast
10.2.2 Canada 麻豆原创 Artificial Blood Substitute Forecast
10.2.3 Mexico 麻豆原创 Artificial Blood Substitute Forecast
10.2.4 Brazil 麻豆原创 Artificial Blood Substitute Forecast
10.3 APAC Artificial Blood Substitute Forecast by Region (2026-2031)
10.3.1 China Artificial Blood Substitute 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Artificial Blood Substitute Forecast
10.3.3 Korea 麻豆原创 Artificial Blood Substitute Forecast
10.3.4 Southeast Asia 麻豆原创 Artificial Blood Substitute Forecast
10.3.5 India 麻豆原创 Artificial Blood Substitute Forecast
10.3.6 Australia 麻豆原创 Artificial Blood Substitute Forecast
10.4 Europe Artificial Blood Substitute Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Artificial Blood Substitute Forecast
10.4.2 France 麻豆原创 Artificial Blood Substitute Forecast
10.4.3 UK 麻豆原创 Artificial Blood Substitute Forecast
10.4.4 Italy 麻豆原创 Artificial Blood Substitute Forecast
10.4.5 Russia 麻豆原创 Artificial Blood Substitute Forecast
10.5 Middle East & Africa Artificial Blood Substitute Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Artificial Blood Substitute Forecast
10.5.2 South Africa 麻豆原创 Artificial Blood Substitute Forecast
10.5.3 Israel 麻豆原创 Artificial Blood Substitute Forecast
10.5.4 Turkey 麻豆原创 Artificial Blood Substitute Forecast
10.6 Global Artificial Blood Substitute Forecast by Type (2026-2031)
10.7 Global Artificial Blood Substitute Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Artificial Blood Substitute Forecast
11 Key Players Analysis
11.1 Aurum Biosciences Ltd.
11.1.1 Aurum Biosciences Ltd. Company Information
11.1.2 Aurum Biosciences Ltd. Artificial Blood Substitute Product Offered
11.1.3 Aurum Biosciences Ltd. Artificial Blood Substitute Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Aurum Biosciences Ltd. Main Business Overview
11.1.5 Aurum Biosciences Ltd. Latest Developments
11.2 HEMARINA SA
11.2.1 HEMARINA SA Company Information
11.2.2 HEMARINA SA Artificial Blood Substitute Product Offered
11.2.3 HEMARINA SA Artificial Blood Substitute Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 HEMARINA SA Main Business Overview
11.2.5 HEMARINA SA Latest Developments
11.3 HbO2 Therapeutics
11.3.1 HbO2 Therapeutics Company Information
11.3.2 HbO2 Therapeutics Artificial Blood Substitute Product Offered
11.3.3 HbO2 Therapeutics Artificial Blood Substitute Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 HbO2 Therapeutics Main Business Overview
11.3.5 HbO2 Therapeutics Latest Developments
11.4 KaloCyte Inc.
11.4.1 KaloCyte Inc. Company Information
11.4.2 KaloCyte Inc. Artificial Blood Substitute Product Offered
11.4.3 KaloCyte Inc. Artificial Blood Substitute Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 KaloCyte Inc. Main Business Overview
11.4.5 KaloCyte Inc. Latest Developments
11.5 SpheriTech Ltd.
11.5.1 SpheriTech Ltd. Company Information
11.5.2 SpheriTech Ltd. Artificial Blood Substitute Product Offered
11.5.3 SpheriTech Ltd. Artificial Blood Substitute Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 SpheriTech Ltd. Main Business Overview
11.5.5 SpheriTech Ltd. Latest Developments
11.6 NuvOx Pharma
11.6.1 NuvOx Pharma Company Information
11.6.2 NuvOx Pharma Artificial Blood Substitute Product Offered
11.6.3 NuvOx Pharma Artificial Blood Substitute Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 NuvOx Pharma Main Business Overview
11.6.5 NuvOx Pharma Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.